Comparison of 2 contrast agents in preventing acute renal failure after angiography

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001986-32-GB

Enrollment

Unknown

Registered

2005-06-29

Start date

2005-07-29

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral vascular or renovascular disease being investigated by angiography

Interventions

Trade Name: Visipaque Pharmaceutical Form: Injection* Trade Name: Niopam Pharmaceutical Form: Injection*

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients over age of 18 undergoing routine angiography as part of the investigation of peripheral or renovascular disease Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Inability to consent Children (below age 18) Pregnancy and lactation Women of child-bearing age (below 55 years) Recent (less than 7 days) administration of any iodinated contrast agent similar to test products Dialysis dependent renal failure

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine whether either agent licensed for angiography is superior to the other in diminishing the incidence of contrast induced nephropathy or acute renal failure after the procedure;Secondary Objective: ;Primary end point(s): Estimations of renal function at 48-72 hours after procedure	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026